$86.5 M

ZYNE Mkt cap, 04-Dec-2018
Zynerba Pharmaceuticals Net income (Q3, 2018)-7.8 M
Zynerba Pharmaceuticals EBIT (Q3, 2018)-8 M
Zynerba Pharmaceuticals Cash, 30-Sep-201866.2 M

Zynerba Pharmaceuticals Income Statement

Annual

USDFY, 2015FY, 2017

Revenue

278.9k

R&D expense

7.4m22.8m

General and administrative expense

5.4m10.0m

Operating expense total

12.8m32.8m

EBIT

(12.5m)(32.8m)

EBIT margin, %

(4493%)

Interest expense

7.4k

Interest income

7.4k519.6k

Pre tax profit

(12.5m)(32.0m)

Income tax expense

(27.5k)

Net Income

(12.6m)(32.0m)

Zynerba Pharmaceuticals Cash Flow

Annual

USDFY, 2015FY, 2016FY, 2017

Net Income

(12.6m)(23.4m)(32.0m)

Depreciation and Amortization

26.0k75.3k94.2k

Accounts Payable

536.4k1.0m1.5m

Cash From Operating Activities

(9.8m)(20.4m)(25.8m)

Purchases of PP&E

(216.3k)(109.6k)(115.4k)

Cash From Investing Activities

(216.3k)(109.6k)(115.4k)

Cash From Financing Activities

42.2m10.0m57.5m

Zynerba Pharmaceuticals Ratios

USDY, 2018

Financial Leverage

1.1 x
Report incorrect company information

Zynerba Pharmaceuticals Employee Rating

00 votes
Culture & Values
N/A
Work/Life Balance
N/A
Senior Management
N/A
Salary & Benefits
N/A
Career Opportunities
N/A
Source